InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.034 0.001 (2.86%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$19 Investor Presentation 1 May 2019 11:37AM $0.018 $0.034 risen by 94.29%
$19 New Cancer Vaccine Trial Data presented at ASCO 2019 29 Apr 2019 9:15AM $0.017 $0.034 risen by 100%
$19 Initial Director's Interest Notice - LR 23 Apr 2019 4:50PM $0.018 $0.034 risen by 88.89%
$19 Leading Global Pharmaceutical Executive Joins Imugene Board 23 Apr 2019 9:39AM $0.017 $0.034 risen by 100%
$19 Appendix 4C - Quarterly and Business Update 16 Apr 2019 9:27AM $0.017 $0.034 risen by 100%
$19 Investor Presentation 16 Apr 2019 8:27AM $0.017 $0.034 risen by 100%
$19 IMU presents new mimotope PD-1 vaccine data at AACR 3 Apr 2019 9:05AM $0.019 $0.034 risen by 78.95%
$19 IMU presents new KEY-Vaxx and B-Vaxx data at AACR 2 Apr 2019 9:44AM $0.020 $0.034 risen by 70%
$19 IMU presents positive new HER-Vaxx data at AACR 2 Apr 2019 9:08AM $0.020 $0.034 risen by 70%
$19 Investor Presentation 26 Mar 2019 12:00PM $0.019 $0.034 risen by 78.95%
$19 IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx 20 Mar 2019 9:03AM $0.019 $0.034 risen by 78.95%
$19 Imugene doses first patient in HER-Vaxx phase 2 trial 14 Mar 2019 9:06AM $0.019 $0.034 risen by 78.95%
$19 IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR 4 Mar 2019 9:17AM $0.020 $0.034 risen by 70%
$19 Half Yearly Report and Accounts 28 Feb 2019 10:04AM $0.017 $0.034 risen by 100%
$19 Pause in Trading 28 Feb 2019 9:56AM $0.017 $0.034 risen by 100%
$19 Imugene Announces Presentation on HER-Vaxx at the AACR 2019 28 Feb 2019 9:08AM $0.017 $0.034 risen by 100%
$19 Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data 26 Feb 2019 10:37AM $0.016 $0.034 risen by 112.50%
$19 Appendix 4C - Quarterly and Business Update 30 Jan 2019 9:28AM $0.018 $0.034 risen by 88.89%
$19 Investor Presentation 10 Jan 2019 9:22AM $0.020 $0.034 risen by 70%
$19 IMU appoints distinguished scientist to the Company SAB 7 Jan 2019 9:37AM $0.018 $0.034 risen by 88.89%
$19 Change of Director's Interest Notice - PH 20 Dec 2018 2:13PM $0.019 $0.034 risen by 78.95%
$19 IMU Meets Endpoints in Phase 1b Gastric Cancer Trial 17 Dec 2018 8:25AM $0.022 $0.034 risen by 54.55%
$19 Change of Director's Interest Notice - LC 21 Nov 2018 9:39AM $0.022 $0.034 risen by 54.55%
$19 Appendix 3B and 708A Notice 21 Nov 2018 9:39AM $0.022 $0.034 risen by 54.55%
$19 Change of Director's Interest Notice - PH 21 Nov 2018 9:39AM $0.022 $0.034 risen by 54.55%

801 - 825 of 1209 results

Page 33 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.